A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib.

被引：0
|
作者：
Duffy, Austin G. [1 ]
Rahma, Osama E. [1 ]
Ulahannan, Susanna Varkey [1 ]
Fioravanti, Suzanne [1 ]
Venkatesan, Aradhana [1 ]
Turkbey, Ismail B. [1 ]
Choyke, Peter L. [1 ]
Trepel, Jane B. [1 ]
Figg, William Douglas [1 ]
Greten, Tim F. [1 ]
机构：
[1] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15177
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
    Duffy, A. G.
    Ulahannan, S. V.
    Cao, L.
    Rahma, O. E.
    Makarova-Rusher, O. V.
    Kleiner, D. E.
    Fioravanti, S.
    Walker, M.
    Carey, S.
    Yu, Y.
    Venkatesan, A. M.
    Turkbey, B.
    Choyke, P.
    Trepel, J.
    Bollen, K. C.
    Steinberg, S. M.
    Figg, W. D.
    Greten, T. F.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2015, 3 (05) : 453 - 461
  • [2] A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)
    Duffy, Austin G.
    Ma, Chi
    Ulahannan, Susanna Varkey
    Makarova-Rusher, Oxana V.
    Fioravanti, Suzanne
    Walker, Melissa
    Venkatesan, Aradhana
    Turkbey, Ismail B.
    Choyke, Peter L.
    Trepel, Jane B.
    Cao, Liang
    Compton, Kathryn
    Figg, William Douglas
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S)
    Abou-Alfa, Ghassan K.
    Capanu, Marinela
    Do, Richard Kinh Gian
    Hollywood, Ellen
    Ly, Michele
    Chou, Joanne F.
    Lee, Jean Kyung
    Connell, Louise Catherine
    Wan, Peter Justin
    Bradley, Margaret
    Harding, James J.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
    Yopp, A.
    Zhu, H.
    Mansour, J.
    Singal, A.
    Arriaga, Y.
    Beg, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S34 - S35
  • [5] A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.
    Smith, Alan D.
    Chan, Kelvin K.
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.
    Zhu, Andrew X.
    Kudo, Masatoshi
    Assenat, Eric
    Cattan, Stephane
    Kang, Yoon-Koo
    Lim, Ho Yeong
    Poon, Ronnie Tung Ping
    Blanc, Jean-Frederic
    Vogel, Arndt
    Chen, Chao-Long
    Dorval, Etienne
    Peck-Radosavljevic, Markus
    Santoro, Armando
    Daniele, Bruno
    Furuse, Junji
    Jappe, Annette
    Perraud, Kevin
    Anak, Ozlem
    Sellami, Dalila B.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)
    Duffy, Austin G.
    Ma, Chi
    Ulahannan, Susanna Varkey
    Makarova-Rusher, Oxana V.
    Fioravanti, Suzanne
    Walker, Melissa
    Turkbey, Baris
    Trepel, Jane
    Cao, Liang
    Steinberg, Seth M.
    Figg, William Douglas
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Prospective evaluation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.
    Adachi, Takuya
    Nouso, Kazuhiro
    Miyahara, Koji
    Dohi, Chihiro
    Wada, Nozomu
    Takeuchi, Yasuto
    Kuwaki, Kenji
    Onishi, Hideki
    Ikeda, Fusao
    Nakamura, Shinichiro
    Shiraha, Hidenori
    Takaguchi, Koichi
    Uematsu, Shuji
    Iwadou, Shouta
    Takuma, Yoshitaka
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Takaki, Akinobu
    Okada, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345